Comparison of diagnostic and treatment guidelines for undescended testis

Jaeho Shin, MD, Ga Won Jeon, MD, PhD

1Division of Pediatric Surgery, Department of Surgery, Inje University Busan Paik Hospital, Busan, Korea; 2Department of Pediatrics, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Cryptorchidism or undescended testis is the single most common genitourinary disease in male neonates. In most cases, the testes will descend spontaneously by 3 months of age. If the testes do not descend by 6 months of age, the probability of spontaneous descent thereafter is low. About 1%–2% of boys older than 6 months have undescended testes after their early postnatal descent. In some cases, a testis vanishes in the abdomen or reascends after birth which was present in the scrotum at birth. An inguinal undescended testis is sometimes mistaken for an inguinal hernia. A surgical specialist referral is recommended if descent does not occur by 6 months, undescended testis is newly diagnosed after 6 months of age, or testicular torsion is suspected. International guidelines do not recommend ultrasonography or other diagnostic imaging because they cannot add diagnostic accuracy or change treatment. Routine hormonal therapy is not recommended for undescended testis due to a lack of evidence. Orchiopexy is recommended between 6 and 18 months at the latest to protect the fertility potential and decrease the risk of malignant changes. Patients with unilateral undescended testes have an infertility rate of up to 10%. This rate is even higher in patients with bilateral undescended testes, with intra-abdominal undescended testis, or who underwent delayed orchiopexy. Patients with undescended testes have a threefold increased risk of testicular cancer later in life compared to the general population. Self-examination after puberty is recommended to facilitate early cancer detection. A timely referral to a surgical specialist and timely surgical correction are the most important factors for decreasing infertility and testicular cancer rates.

Key words: Anorchia, Cryptorchidism, Fertility, Orchiopexy, Testicular neoplasm

Key message
Primary caregivers should consider surgical specialist referral of patients with undescended testis if no descent occurs by 6 months, undescended testis is newly diagnosed after 6 months of age, or testicular torsion is suspected. Orchiopexy is recommended between 6 and 18 months at the latest. The original location of the testes and the age at orchiopexy are predictive factors for infertility and malignancy later in life.

Introduction

Cryptorchidism or undescended testis (a testis that is not in the scrotum) is the single most common genitourinary disease in male neonates. Normal testicular descent to the scrotum usually occurs between 25 and 35 weeks of gestation. Undescended testis is diagnosed at birth at a rate of 1%–4% in term infants and up to 45% in preterm infants. Many cases of undescended testes will descend spontaneously to the scrotum by 3 months of age. Testicular descent after 3 months of age is also possible, especially in preterm infants. However, in some preterm infants, the testes do not descend until term age or vanish in the abdomen. In some cases, a testis that was present in the scrotum reascends after birth. The mechanisms of normal testicular descent, testicular reascent, and testicular regression have not been fully established yet. About 1%–2% of boys older than 6 months develop undescended testis after its early postnatal descent. Undescended testis is known to be associated with decreased fertility and increased malignancy rates. Timely referral to a surgical specialist and timely surgical correction may improve fertility rates and decrease malignancy rates related to undescended testis. Controversy persists about the effectiveness of hormonal therapy, timing of surgical therapy, and testicular outcomes of undescended testis. In this review, we discuss the diagnosis, differential diagnosis, hormonal therapy, and timing of surgical therapy of undescended testis based on international guidelines as well as fertility and the risk of testicular cancer of undescended testis.
Risk factors

Important risk factors of undescended testis are preterm birth (<37-week gestation), low birth weight (<2.5 kg), and intrauterine growth restriction. A family history of undescended testis, associated hormonal disorders (such as congenital adrenal hyperplasia), associated penile abnormalities (such as hypospadias), slow fetal growth (such as Down syndrome), and disorders of sex development can increase the risk of undescended testis. A young maternal age is protective against the development of undescended testis. Older maternal age is related to undescended testis. The relative risk is 1.8 with a maternal age ≥30 years and 2.5 with a maternal age ≥40 years. However, controversy persists regarding the role of maternal old age and the development of undescended testis. Maternal smoking during pregnancy is associated with an increased risk of undescended testis.

Classification

Testicular position is classified as intra-abdominal, inguinal, supra-scrotal, high scrotal, and scrotal according to the process of testicular descent. Intra-abdominal testis is not palpable. Inguinal testis is sometimes palpable. Supra-scrotal and high scrotal testes are palpable. Scrotal testis is considered normal, as it lies in the bottom of the scrotum (Fig. 1).

Undescended testis is classified according to its location and presence (Table 1). In palpable undescended testis, the testis may be palpable in the inguinal canal or ectopic area such as the inner thigh, femoral, pubic, and perineal regions. In impalpable undescended testis, the testis may be located in the abdomen, inguinal canal, or internal inguinal ring. It may also be absent. When the testis is found in the scrotum, sometimes in a supra-scrotal position, it is called retractile testis and has finished its descent. It can be pulled gently to the bottom of the scrotum and may stay there for a while, which is often considered normal. However, up to one-third of retractile testis can reascend and become undescended, which is not considered normal.

Reascended testis, which a previously descended testis ascends to a higher position, comprises some proportion of cases of undescended testis. An abnormally persistent fibrotic remnant of the processus vaginalis, patent processus vaginalis, and nonorthotopic gubernacular insertion (higher insertion) are suggested causes of reascended testis.

Diagnosis

The external genitalia must be inspected thoroughly, especially in patients whose bilateral testes are not palpable. Bilateral impalpable testes can be associated with hormonal failure, conditions such as prune belly syndrome, a posterior urethral valve, abdominal wall defects, or neural tube defects. The patient’s groin and scrotum must be palpated from the inguinal canal toward the pubis in a supine or frog-leg position with warm fingers. The inner thigh, femoral, pubic, perineal, and penile regions also must be palpated to find the ectopic testis. Testis can become palpable in a sitting or squatting position but not in a supine position.

Unilateral impalpable testis associated with contralateral compensatory hypertrophy suggests the absence of the ipsilateral testis, meaning vanishing testis or testicular regression. Antenatal vascular accident and underlying antenatal endocri-

Table 1. Classification of undescended testes

| Classification | Location of testis                  | Absent |
|----------------|------------------------------------|--------|
| Palpable       | Inguinal, retractile, ectopic       |        |
| Impalpable     | Intra-abdominal, inguinal, ectopic  |        |

Fig. 1. Testicular position. Testicular position is classified as intra-abdominal, inguinal, suprascrotal, high scrotal, and scrotal according to the process of testicular descent. Intra-abdominal testes are not palpable. Inguinal testes are sometimes palpable. Suprascrotal and high scrotal testes is palpable. Scrotal testis is considered normal as it lies in the bottom of scrotum. UDT, undescended testis.
Imaging studies

Table 2. Diagnostic guidelines of undescended testes

| AUA (30) | BAPS/BAUS (31) | CUA (32) | EAU (33) |
|----------|----------------|----------|----------|
| **Surgical specialist referral** | If there is no descent by 6 months, or if UDT is newly diagnosed >6 months of age. | If there is no descent by 6 months, or if UDT is newly diagnosed >6 months of age. | If there is no descent by 6 months, or if UDT is newly diagnosed >6 months of age. | If there is no descent by 6 months. |
| **Endocrine assessment for bilateral UDT** | Recommended | Recommended | Recommended | Recommended |
| **Diagnostic exploratory laparoscopy for impalpable UDT** | Recommended | Recommended | Recommended | Recommended |
| **Imaging study** | Not recommended | Not recommended | Not recommended | Not recommended |

AUA, American Urological Association; BAPS/BAUS, British Association of Pediatric Surgeons/British Association of Urologic Surgeons; CUA, Canadian Urological Association; EAU, European Association of Urology; UDT, undescended testes.
low as about 20% in prescrotal or inguinal palpable undescended testis, but not in impalpable tests.\textsuperscript{41} However, LHRH therapy can cause hydrocele requiring surgery, penile growth, pubic hair, frequent erection, and behavioral problems.\textsuperscript{41} GnRH/LHRH therapy can also harm germ cells and suppress their numbers.\textsuperscript{45} Long-term follow-up of GnRH/LHRH therapy has not been reported yet. Besides, the success rate of testicular descent with hormonal therapy is low and the risk of testicular reascending is high, although the testes descend with hormone therapy. On the other hand, in a small study of 10 boys, GnRH agonist therapy with orchiopexy improved impaired mini-puberty and spermatogonia in patients with bilateral undescended testes.\textsuperscript{46}

According to international guidelines, routine hormonal therapy with hCG or GnRH/LHRH for undescended testes, is not recommended due to the lack of evidence as previously described (Table 4).\textsuperscript{30,32,33} Consensus is developing that orchiopexy but not hormonal therapy is required in the first year of life.\textsuperscript{10,47,48} In an identified hormonal defect in congenital hypogonadotropic hypogonadism or partial androgen insensitivity, hormonal therapy can be considered by a pediatric endocrinologist. However, debate persists over whether hormonal therapy is useful as an adjunct to orchiopexy to stimulate germ cell development, although hormonal therapy for undescended testes is ineffective.

### Table 3. Diagnostic imaging studies for undescended testes

| Imaging study is not recommended\textsuperscript{30-33} |
|---|
| Reasons |
| 1. Imaging study cannot add diagnostic accuracy |
| 1) High false negative rate (low sensitivity) if the size of testis is small |
| 2) Cannot determine whether a testis is present or not |
| 3) Cannot localize impalpable testes |
| 4) Cannot rule out an intra-abdominal testis |
| 2. Imaging study cannot change management |
| 3. Diagnostic exploratory laparoscopy is inevitable regardless of the result of imaging study. |
| Practitioners perform imaging study\textsuperscript{38,39} |
| Reasons |
| 1. Imaging study may add objective assessment of pre-operative testicular position and size. |
| 2. Imaging study may add objective assessment of post-operative testicular size. |
| 3. Imaging study may be helpful for any legal problem following orchiopexy. |
| 1) Can provide objective size of testis or atrophy testis before orchiopexy |

### Table 4. Treatment guidelines and outcomes of undescended testes

| AUA\textsuperscript{30} | BAPS/BAUS\textsuperscript{31} | CUA\textsuperscript{32} | EAU\textsuperscript{33} |
|---|---|---|---|
| Hormonal therapy | Not recommend | Not discussed | Not recommend | Not recommend |
| Age at orchiopexy | If no descent by 6 months, surgery should be done within the next year. | 6-18 months of age | 6-18 months of age | 6-12 months of age (<12 months of age, by 18 months at the latest) |
| Fertility | Decreased fertility and paternity in bilateral UDT | Not discussed | Decreased paternity in bilateral UDT | Decreased fertility and paternity in bilateral UDT, age at orchiopexy is important. |
| Testicular cancer | Increased risk in intra-abdominal UDT, decreased risk in orchiopexy before puberty (compared to orchiopexy after puberty) | Not discussed | Decreased risk in orchiopexy before puberty, but still above that of noncryptorchid male | Increased risk of testicular cancer, decreased risk in orchiopexy before puberty (compared to orchiopexy after puberty) |
| Self-examination after puberty | Recommended (monthly) | Not discussed | Recommended, no need for long-term urological follow-up | Recommended |

AUA, American Urological Association; BAPS/BAUS, British Association of Pediatric Surgeons/British Association of Urologic Surgeons; CUA, Canadian Urological Association; EAU, European Association of Urology; UDT, undescended testis.

### Surgical therapy

If the testes do not descend at 6 months of age, the probability of spontaneous descent thereafter is low.\textsuperscript{49} International guidelines recommend surgical specialist referral from primary caregivers if descent does not occur by 6 months,\textsuperscript{30-33} or if undescended testis is newly diagnosed after 6 months of age (Table 2).\textsuperscript{30,32}

Undescended testis interferes with the differentiation of primitive germ cells that produce germ cells and finally spermatogenesis.\textsuperscript{40} Thus, delayed orchiopexy decreases germ cell production, testicular volume, and fertility.\textsuperscript{50} To enhance spermatogenesis and increase testicular volume, the recommended age of orchiopexy decreased from 48–72 months in 1986 to 18–24 months and recently 6–12 months of age.\textsuperscript{51,52} However, large number of boys still undergo orchiopexy after 18 months of age. The median age for orchiopexy was 48 months between 1993 and 2000 and 36 months between 2000 and 2010 in 3784 orchiopexies over 22 years.\textsuperscript{51} The most common age at orchiopexy was 12–18 months. The second most common age was 18–30 months between 1993 and 2014.\textsuperscript{51} Among patients undergoing orchiopexy, 77% were older than 1 year and 42% were older than 2 years at orchiopexy.\textsuperscript{6}

Histological evidence suggests that orchiopexy should be performed within the first year of life (no later than 2 years of age) to protect fertility.\textsuperscript{53} A recent systematic review found no difference in testicular volume or spermatogonia in orchiopexy before versus after 1 year of age, although better fertility potential with orchiopexy performed before 1 year of age was found.\textsuperscript{54} To protect fertility potential and decrease malignant changes, surgical exploration and orchiopexy are recommended between
six and 18 months of age (Table 4).

Testicular torsion, a surgical emergency, is not common in neonates, and torsion of undescended testis does not present the typical painful swelling of the scrotum; rather, it appears as swelling of the groin. Therefore, torsion of undescended testis is not easy to recognize. Undescended testis and an ipsilateral inguinal mass with groin swelling must be suspected as torsion of undescended testis. Ultrasonography is not helpful to differentiate between incarcerated inguinal hernia and torsion of undescended testis; rather, urgent referral and surgical exploration are required.55

Undescended testis and fertility

Hutson et al.56 reported that gonocytes transform into spermatogonic stem cells at 3–9 months of age. This postnatal step is confused in cases of undescended testis. Arrested gonocytes in undescended testis can cause germ cell malignancies after puberty. Abnormalities in gonocyte transformation can cause infertility. Thus, the original location of the undescended testis is important in the risk of testicular cancer and fertility. Age at orchiopexy is also an important factor for predicting fertility.13

Compared to fertility rate (number of offspring born per mating pair) in the general population, that in patients with undescended testis is decreased, although they underwent orchiopexy. Patients with bilateral undescended testes have an increased infertility rate compared to those with a unilateral undescended testis and the general population.57 Infertility rates of patients with unilateral undescended testes are up to 10%, which is even higher in patients with bilateral undescended testes.58,59 The paternity rate (actual potential of fatherhood) was reportedly 62% in bilateral undescended testes, 89% in unilateral undescended testis, and 94% in the general United States population.60 The paternity rate among patients with bilateral undescended testes was as low as 33%–65% in Canada. In cases of unilateral undescended testis, it was similar to that in a general Canadian population (up to 90%).32 Testicular atrophy has been reported in less than one third of patients, depending on the original location, despite the success of surgical procedures.49 Intra-abdominal undescended testis is associated with a high risk of postsurgical atrophy despite successful orchiopexy, which is 15-fold higher than inguinal undescended testis.50 Untreated bilateral undescended testes show a 100% oligospermia rate.61 Patients with bilateral undescended testes without germ cells on biopsy show a 75%–100% risk of infertility.62

Undescended testis and testicular cancer

In a meta-analysis, patients with undescended testes are at a threefold increased risk of testicular cancer later in life.7 In another study, the risk of testicular cancer is increased sevenfold in patients with undescended testes and 32-fold if orchiopexy is delayed after puberty.63 A significantly increased risk of testicular cancer in intra-abdominal testis was reported in the past. However, the risk of testicular cancer decreased in patients who underwent orchiopexy before puberty compared to those who underwent orchiopexy after puberty.61,63,64 The relative risk of testicular cancer in patients who underwent orchiopexy before puberty (<13 years of age) was 2.2, which increased to 5.4 in patients who underwent orchiopexy after puberty versus the general population.64

Formal long-term urological follow-up of patients with undescended testes is not recommended.32 Screening and self-examination during and after puberty are recommended because of the increased risk of testicular cancer (Table 4).

Conclusion

Timely referral to a surgical specialist and timely surgical correction may improve fertility and decrease malignancy rates related to undescended testis. Primary caregivers should consider surgical specialist referral of patients with undescended testis if no descent occurs by 6 months, undescended testis is newly diagnosed after 6 months of age, or testicular torsion is suspected. The use of ultrasonography and other diagnostic imaging techniques is not recommended because they cannot add diagnostic accuracy or change treatment. Orchiopexy is recommended between 6 and 18 months at the latest. The fertility rate is low in patients with bilateral undescended testes, although orchiopexy is successful. The risk of testicular cancer in patients with undescended testis is increased compared to that in the general population. The original location of the testes and the age at orchiopexy are predictive factors for fertility and malignancy later in life. Self-examination after puberty is recommended to facilitate early cancer detection.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

See the commentary “Undescended testis: importance of a timely referral to a surgical specialist” via https://doi.org/10.3345/cep.2020.00115.

References

1. Sijstermans K, Hack WW, Meijer RW, van der Voort-Doedens LM. The frequency of undescended testis from birth to adulthood: a review. Int J Androl 2008;31:1-11.
2. Holland AJ, Nassar N, Schneuer FJ. Undescended testes: an update. Curr Opin Pediatr 2016;28:388-94.
3. Radmayr C, Dogan HS, Hoebeke P, Kovara R, Nijman R, Silay S, et al. Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. J Pediatr Urol 2016;12:335-43.
4. Boisen KA, Kaleva M, Main KM, Virtanen HE, Haavisto AM, Schmidt
IM, et al. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. Lancet 2004;363:1264-9.
5. Kiuru-Hanninen T, Koskenniemi J, Dunkel L, Toppari J, Sankilampi U. Postnatal testicular activity in healthy boys and boys with cryptorchidism. Front Endocrinol (Lausanne) 2019;10:489.
6. Nah SA, Yeo CS, How GY, Allen JC, Jr., Lakshmi NK, Yap TL, et al. Undescended testes: 513 patients' characteristics, age at orchidopexy and patterns of referral. Arch Dis Child 2014;99:401-6.
7. Lip SZ, Murchison LE, Cullis PS, Gowan L, Carachi R. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 2013;98:20-6.
8. Cook MB, Akre Q, Forman D, Madigan MP, Richardt L, McGlynn KA. A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer—experiences of the son. Int J Epidemiol 2010;39:1605-18.
9. Mavrogenis S, Urban R, Czeizel AE. Characteristics of boys with the so-called truly undescended tests diagnosed at the third postnatal month -a population-based case-control study. J Matern Fetal Neonatal Med 2015;28:1152-7.  
10. Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C, et al. Risk factors for cryptorchidism. Nat Rev Urol 2017;14:53-48.
11. McGlynn KA, Graubard BI, Kleinbaum DA, Longnecker MP. Risk factors for cryptorchidism among populations at differing risks of testicular cancer. Int J Epidemiol 2006;35:787-95.
12. Hackshaw A, Rodeck C, Boniface T. Maternal smoking in pregnancy and birth defects: a systematic review based on 173,687 malformed cases and 11.7 million controls. Hum Reprod Update 2011;17:589-604.
13. Zhang L, Wang XH, Liu TZ, Zhang WB, Zheng H, et al. Maternal gestational smoking, diabetes, alcohol drinking, pre-pregnancy obesity and the risk of cryptorchidism: a systematic review and meta-analysis of observational studies. PLoS One 2015;10:e0119006.
14. Cho A, Thomas J, Perera R, Cherian A. Undescended testes. BMJ 2019;364:l926.
15. Cryptorchidism: a prospective study of 7500 consecutive male births, 1984-8. John Radcliffe Hospital Cryptorchidism Study Group. Arch Dis Child 1992;67:892-9.
16. Keys C, Helouy Y. Retractile testes: a review of the current literature. J Pediatr Urol 2012;95:3-6.
17. Yap E, Nataraja RM, Pacilli M. Undescended testes: what general practitioners need to know. Aust J Gen Pract 2019;48:53-48.
18. Haid B, Silay MS, Radford A, Rein P, Bansalos E, Oswald J, et al. Late ascended tests: is non-orthotopic gubernacular insertion a confirmation of an alternative embryological etiology? J Pediatr Urol 2019;15:71.e1-6.
19. Hutson JM, Balic A, Nation T, Southwell B. Cryptorchidism. Semin Pediatr Surg 2010;19:215-24.
20. Cendron M, Huff DS, Keating MA, Snyder JM 3rd, Duckett JW. Anatomical, morphological and volumetric analysis: a review of 759 cases of testicular maldescent. J Urol 1993;149:570-3.
21. Braga LH, Kim S, Farrokhlyar F, Lorenzo AJ. Is there an optimal concurrent testicular cut-off size that predicts monorchism in boys with nonpalpable testicles? J Pediatr Urol 2014;10:693-8.
22. Haid B, Rein P, Oswald J. Undescended testes: diagnostic algorithm and treatment. Eur Urol Focus 2017;3:155-7.
23. Ito Y, Kitamura H. Antenatal ultrasound visualization of left testis that than vanished after birth. Pediatr Int 2014;56:928-30.
24. Dangé P, Salgado C, Reyes-Muñiga M, Schneck F, Oest M, Simó-Lucasa S. Testicular hypoplasia is driven by defective vascular formation. Urology 2017;101:94-8.
25. Ganni P, Vacchiani N, Udayasankar U. Intratertiary testicular torsion. J Urol 2014;191:217-8.
26. Yoshi K, Naiki Y, Terada Y, Fukami M, Horikawa R. Mismatch between fetal sexing and birth phenotype: a case of complete androgen insensitivity syndrome. Endocr J 2018;65:221-5.
27. Deeb A, Hughes IA. Inguinal hernia in female infants: a cue to check the sex chromosomes? BJU Int 2005;96:401-3.
28. Raj V, Redkar R, Krishna S, Tewari S. Rare case of transverse testicular ectopia - case report and review of literature. Int J Surg Case Rep 2017;41:407-10.
29. Naji H, Peristers A, Steenman J, Svensson JF, Wester T. Transverse testicular ectopia: three additional cases and a review of the literature. Pediatr Surg Int 2012;28:703-6.
30. Kolon TF, Herndon CD, Baker LA, Baskin LS, Baxter CG, Cheng EY, et al. Evaluation and treatment of cryptorchidism: AUA guideline. J Urol 2014;192:337-45.
31. British Association of Pediatric Surgeons, Commissioning guide: paediatric orchidopexy for undescended testes. London: Royal College of Surgeons of England (RCS); British Association of Urological Surgeons (BALS), 2015.
32. Braga LH, Lorenzo AJ, Romao RLP. Canadian Urological Association-Pediatric Urologists of Canada (CUA-PUC) guideline for the diagnosis, management, and followup of cryptorchidism. Can Urol Assoc J 2017;11:E251-60.
33. Radmayr C, Bogaert G, Dogan HS, Koivara R, Nijman JM, Stein R, et al. EAU Guidelines on Paediatric Urology 2018. Arnhem (The Netherlands): European Association of Urology; European Society for Paediatric Urology, 2018.
34. Taitan GE, Copp HL. Diagnostic performance of ultrasound in nonpalpable cryptorchidism: a systematic review and meta-analysis. Pediatrics 2011;127:119-28.
35. Taitan GE, Yee JH, Copp HL. Imaging use and cryptorchidism: determinants of practice patterns. J Urol 2011;185:1882-7.
36. Elder JS. Ultrasoundography is unnecessary in evaluating boys with a nonpalpable testis. Pediatrics 2002;110:748-51.
37. Esposito C, Escolino M, Savanelli A, Alicchio F, Roberti A, Settini A. Ultrasoundography is unnecessary and misleading in evaluating boys with a nonpalpable testes and can be a cause of a legal process. Med Sci Law 2013;53:247-8.
38. Jedrzejewski G, Wieczorek AE, Osemplak P, Nachulewicz P. The role of ultrasound in the management of undescended testes before and after orchidopexy - an update. Medicine (Baltimore) 2016;95:e5731.
39. Lee SW, Kim KS, Chang HS, Ryu DS. Comprehension and practice patterns toward cryptorchidism in Korean Urologists. Korean J Urol 2009;50:169-78.
40. Chua ME, Mendoza JS, Gaston MJ, Luna SL Jr., Morales ML Jr. Hormonal therapy using gonadotropin releasing hormone for improvement of fertility index among children with cryptorchidism: a meta-analysis and systematic review. J Pediatr Surg 2014;49:1659-67.
41. Li T, Gao L, Chen P, Bu S, Cao D, Yang L, et al. A systematic review and meta-analysis of comparative studies assessing the efficacy of luteinizing hormone-releasing hormone therapy for children with cryptorchidism. Int Urol Nephrol 2016;48:635-44.
42. Hjertkvist M, Lackgren G, Ploen L, Bergh A. Does HCG treatment induce inflammation-like changes in undescended testes in boys? J Pediatr Surg 1993;28:254-8.
43. Waldschmidt J, el-Dessouky M, Priever A. Therapeutic results in cryptorchidism after combination therapy with LH-RH nasal spray and hCG. Eur J Pediatr 1987;146 Suppl 2:S31-4.
44. Ong C, Hasthorpe S, Hutson JM. Germ cell development in the descend- and cryptorchid testis and the effects of hormonal manipulation. Pediatr Surg Int 2005;21:240-54.
45. Cortes D, Thorup J, Videfeldt J. Hormonal treatment may harm the germ cells in 11 to 3-year-old boys with cryptorchidism. J Urol 2000;163:1290-2.
46. Vincel B, Verkaucks G, Biluvs V, Dasevičius D, Malcius D, Jones B, et al. Gonadotropin-releasing hormone agonist corrects defective mini-puberty in boys with cryptorchidism: a prospective randomized study. Biomed Res Int 2018;2018:4651218.
47. Hutson JM, Thorup J. Evaluation and management of the infant with cryptorchidism. Curr Opin Pediatr 2015;27:520-4.
48. Steinbrecher H. The undescended testis: working towards a unified care pathway for 2014. Arch Dis Child 2014;99:397-8.
49. Schnue FJ, Holland AJ, Pereira G, Jamieson S, Bower C, Nassar N. Age at surgery and outcomes of an undescended testis. Pediatrics 2016;137:e20152768.
50. Chan E, Wayne C, Nasr A. Ideal timing of orchiopexy: a systematic review. Pediatr Surg Int 2014;30:87-97.
51. Wei Y, Wu SD, Wang YC, Lin T, He DW, Li XL, et al. A 22-year retrospective study: educational update and new referral pattern of age at orchiopexy. BJU Int 2016;118:987-93.
52. Ritzen EM, Bergh A, Bjerknes R, Christiansen P, Cortes D, Haugen SE, et al. Nordic consensus on treatment of undescended testes. Acta Paediatr 2007;96:638-43.
53. Park KH, Lee JH, Han JJ, Lee SD, Song SY. Histological evidences suggest recommending orchiopexy within the first year of life for children with unilateral inguinal cryptorchid testis. Int J Urol 2007;14:616-21.
54. Allin BSR, Dumann E, Fawkner-Corbett D, Kwok C, Skerritt C. Systematic review and meta-analysis comparing outcomes following orchiopexy for cryptorchidism before or after 1 year of age. BJ S Open 2018; 2:1-12.
55. Kargl S, Haid B. Torsion of an undescended testis - a surgical pediatric emergency. J Pediatr Surg 2020;55:660-4.
56. Hutson JM, Li R, Southwell BR, Petersen BL, Thorup J, Cortes D. Germ cell development in the postnatal testis: the key to prevent malignancy in cryptorchidism? Front Endocrinol (Lausanne) 2012;3:176.
57. Gracia J, Sanchez Zalabardo J, Sanchez Garcia J, Garcia C, Ferrandez A. Clinical, physical, sperm and hormonal data in 251 adults operated on for cryptorchidism in childhood. BJU Int 2000;85:1100-3.
58. Carson JS, Casick R, Mercer A, Ashley A, Abdessalam S, Raynor S, et al. Undescended testes: does age at orchiopexy affect survival of the testis? J Pediatr Surg 2014;49:770-3.
59. Murphy F, Paran TS, Puri P. Orchidopexy and its impact on fertility. Pediatr Surg Int 2007;23:625-32.
60. Lee PA, O’Leary LA, Songer NJ, Coughlin MT, Bellinger MF, LaPorte RE. Paternity after unilateral cryptorchidism: a controlled study. Pediatrics 1996;98:676-9.
61. Lee PA. Fertility after cryptorchidism: epidemiology and other outcome studies. Urology 2005;66:427-31.
62. Cortes D, Thorup JM, Beck BL. Quantitative histology of germ cells in the undescended testes of human fetuses, neonates and infants. J Urol 1995;154:1188-92.
63. Walsh TJ, Dall’Era MA, Croughan MS, Carroll PR, Turek PJ. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol 2007;178:1440-6; discussion 6.
64. Pettersson A, Richiardi L, Nordenskjold A, Kajser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007;356:1835-41.

How to cite this article: Shin J, Jeon GW. Comparison of diagnostic and treatment guidelines for undescended testes. Clin Exp Pediatr 2020;63:415-21. https://doi.org/10.3345/cep.2019.01438